Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Corneal Collagen Cross-linking (Epi-on vs Epi-off)
NCT01708538Phase 3
Key facts
- Status
- Unknown
- Start
- Oct 2012
- Primary completion
- Oct 2024
- Countries
- 1
- Sponsor
- Rush Eye Associates
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- riboflavin
- Conditions
- keratoconuscorneal ectasia
01
Overview
Phase 3, randomised trial of riboflavin in keratoconus and corneal ectasia (2 arms), sponsored by Rush Eye Associates. Primary endpoints: Visual acuity at 1 year and Keratometry measurements at 1 year. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Epithelium on
Epi not removed during CXL treatment
Epithelium off
Epi removed before CXL treatment
03
Who it enrols
Patients aged 10-70 with a diagnosis of corneal ectasia disorder, including keratoconus, who are willing to participate.
04
Endpoints
Primary
Visual acuity
Keratometry measurements
Beyond the preview
Go deeper on NCT01708538.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708538.